Previously we showed that biodegradable nanoparticles containing poly-IC or CpG oligodeoxynucleotide (ODN) together with ovalbumin (OVA) were efficient at inducing MHC-restricted presentation of OVA peptides in dendritic cells. The CTL-inducing activities of the nanoparticles were examined in the present study. Nanoparticles containing poly-IC or CpG ODN together with OVA were prepared using biodegradable polymer poly(D,L-lactic acid-co-glycolic acid), and then were opsonized with mouse IgG. The nanoparticles were injected into the tail vein of mice, and 7 days later the OVA-specific CTL activities were measured using an in vivo CTL assay. Immunization of mice with the nanoparticles containing poly-IC or CpG ODN together with OVA elicited potent OVA-specific CTL activity compared to those containing OVA only. In accordance with these results, nanoparticles containing poly-IC or CpG ODN together with OVA exerted potent antitumor activity in mice that were subcutaneously implanted with EG7.OVA tumor cells. These results show that encapsulation of poly-IC or CpG ODN together with antigen in biodegradable nanoparticles is an effective approach for the induction of potent antigen-specific CTL responses in vivo. The cross-presentation pathway, which allows MHC-I-restricted presentation of exogenous antigen, appears to be an obligatory mechanism for the generation of CTL responses to antigens that are expressed only in nonprofessional antigen presenting cells (APCs) (2) (3) (4) (5) (6) . In the absence of such a mechanism, viral or tumor antigens expressed in nonprofessional APCs could escape immunosurveilance because CTL responses can only be induced efficiently for the antigens presented via class I MHC molecules on professional APCs (2-6).
Delivery of antigens using nanoparticles prepared from biodegradable polymers such as poly(D, L-lactic acid-co-glycolic acid) (PLGA) into professional APCs is an efficient method for the induction of potent CTL responses. We and others have also shown that PLGA particle-mediated antigen delivery enhances and prolongs the MHC class I-restricted presentation of the exogenous antigens (cross-presentation) in dendritic cells (DCs) (7) (8) (9) (10) . PLGA-nanoparticles have also been shown to deliver antigens to APCs efficiently and generate Th1-type immune responses even against poor immunogens (11, 12) . In our hand, antigens encapsulated with PLGA were at least 100 times more effective in inducing MHC-I-restricted presentation of exogenous antigen in DCs (13) . Another advantage of nanoencapsulation would also be the protection of the encapsulated antigens and the immunomodulators from degradation by serum enzymes (14) .
Recently, we showed that nanoparticles containing poly-IC or CpG ODN together with ovalbumin (OVA) increases and prolongs both MHC class I-and class II-restricted presentation IMMUNE NETWORK Vol. 13 of OVA peptides in DCs (9) . In the present study, we examined the capability of the nanoparticles to induced OVA-specific CTL responses in mice.
Nanoparticles containing poly-IC or CpG ODN together with OVA were prepared using a biocompatible/biodegradable polymer, PLGA, as described earlier (9) . The poly-IC used in the present study was purchased from Invivogen (San Diego, CA, USA). Unmethylated CpG oligodeoxynucleotide (ODN), 5'-TCC ATG ACG TTC CTG ATG CT-3', was synthesized by the Bionics Co. Ltd (Seoul, Korea). The amounts of poly-IC and CpG DNA contained in the nanoparticles were 1.40 and 2.01μg/mg nanoparticles, respectively. The average content of OVA was 21.68μg/mg nanoparticles. For opsonization, OVA-specific mouse IgG (mIgG) or was attached covalently to the nanoparticles using (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) (EDC, Pierce, Rockford, IL, USA) as previously described (9) .
The ] ) were compared in mice. In this experiment, the nanoparticles were injected intravenously into tail veins of mice (100μg as OVA/mouse). Seven days later, an in vivo CTL assay was performed in the mice using CFSE-labeled syngeneic target cells, as described in detail in the earlier paper (9) . Fig. 1A shows representative histograms of the cells isolated from the spleens. Addition of poly-IC or CpG to OVA-nanoparticles significantly increased their ability to induce OVA-specific CTLs in the spleens (Fig. 1B) and lymph nodes (Fig. 1C) OVA＋CpG] ), intravenously into tail veins of the mice (10 μg as OVA or BSA/mouse). Seven days later, the mice were subcutaneously implanted with EG7.OVA tumor cells (5×10 5 / mouse), which is a mouse lymphoma expressing OVA. Two days later, the mice were immunized with the same nanoparticles intravenously into tail veins of the mice. The tumor size was measured with a slide caliper and expressed as a tumor index, determined as the square root of (major axis×minor axis). As shown in Fig. 2A , the growth of tumors was obvious from day 14 after tumor cell implantation, and reached to average size of 3.76 cm 3 Because the EG7.OVA cells express only MHC-I molecules and not MHC-II molecules, it is reasonable to speculate that the antitumor activity shown by the nanoparticles is the reflection of the OVA-specific CTL activity (15) . In addition, it is noteworthy to note that the TLR agonists, poly-IC and CpG, were entrapped inside the PLGA-nanoparticles. Encapsulation prevents not only the systemic effects of the TLR agonists, but also the enzymatic degradation of the TLR agonists (9, (14) (15) (16) (17) (18) .
Robust induction of CTL activity is important in the immunotherapy of tumors and viral infections. Recently, our laboratory has been involved in the development of strategies to enhance the MHC-I-restricted antigen presentation of exogenous antigen (8, 9, 19, 20) . We showed that nanoencapsulation of poly-IC or CpG together with OVA is an efficient approach to increase and prolong the MHC-restricted presentation of OVA peptides in dendritic cells (9) . We also showed that IgG-opsonized PLGA-nanoparticles with a mean size of 1.1μm would be the choice of biodegradable carriers for the targeted-delivery of protein antigens for cross-priming in vivo (20) . The present study confirms that nanoparticles containing poly-IC or CpG ODN together with OVA induce potent antitumor CTL activities in mice, and the OVA-specific CTL activity is sufficient to inhibit the growth of EG7.OVA tumor cells in mice. Our study also shows that encapsulation of poly-IC or CpG ODN together with antigen in biodegradable nanoparticles is an effective approach for the induction of potent antigen-specific CTL responses.
